Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
Simon A BroadleyErnest Willoughby

Abstract

Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of therapies that have an impact on the long term outcome of the disease have emerged over the past 20 years. In this three part series we review the practicalities, benefits and potential hazards of each of the currently available and emerging treatment options for MS. We pay particular attention to ways of abrogating the risks of these therapies and provide advice on the most appropriate indications for using individual therapies. In Part 1 we review the history of the development of MS therapies and its connection with the underlying immunobiology of the disease. The established therapies for MS are reviewed in detail and their current availability and indications in Australia and New Zealand are summarised. We examine the evidence to support their use in the treatment of MS.

References

Jul 1, 1991·Neurology·B G WeinshenkerG P Rice
Jan 1, 1988·Annals of the New York Academy of Sciences·K Ellerman, S Brostoff
Feb 1, 1988·Italian Journal of Neurological Sciences·C MilaneseF Corridori
Aug 13, 1987·The New England Journal of Medicine·M B BornsteinV Spada
Jan 1, 1984·Medical Microbiology and Immunology·T EbinaM Ohta
Nov 1, 1994·The Journal of Clinical Investigation·R R Lobb, M E Hemler
Jun 1, 1995·Journal of Clinical Pharmacology·S De CastroS Beni
Jul 17, 1999·Multiple Sclerosis : Clinical and Laboratory Research·A M RostamiD Pfohl
Oct 16, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·C H PolmanA J Thompson
Apr 25, 2000·Multiple Sclerosis : Clinical and Laboratory Research·I L TanF Barkhof
Jul 6, 2000·Immunopharmacology·A C Allison, E M Eugui
Apr 9, 2002·Multiple Sclerosis : Clinical and Laboratory Research·J A FrankT Leist
Apr 9, 2002·Multiple Sclerosis : Clinical and Laboratory Research·G P A Rice
Jun 5, 2002·Current Opinion in Neurology·Bernhard HemmerNorbert Sommer
Sep 27, 2002·Annals of Neurology·Nancy L SicotteRhonda R Voskuhl

❮ Previous
Next ❯

Citations

Nov 26, 2016·Multiple Sclerosis : Clinical and Laboratory Research·Pieter A Van DijkIngrid van der Mei
Feb 15, 2018·Current Neurology and Neuroscience Reports·Suzanne NielsenMichael Farrell
Mar 29, 2019·The Medical Journal of Australia·Anneke Van Der WaltVilija Jokubaitis
Jun 21, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·Jing ChenIngrid A F van der Mei
Aug 1, 2015·The Medical Journal of Australia·Simon A BroadleyErnest Willoughby
Dec 19, 2018·Multiple Sclerosis Journal - Experimental, Translational and Clinical·L De MeijerA Van der Walt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.